SGLT-2 Inhibitors May Cut Dementia Risk in Patients With Diabetes
By Lori Solomon HealthDay Reporter
TUESDAY, Sept. 3, 2024 -- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a study published online Aug. 28 in The BMJ.
Anna Shin, from Seoul National University Bundang Hospital in South Korea, and colleagues compared the risk for dementia associated with SGLT-2 inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors in adults (aged 40 to 69 years) with type 2 diabetes. The analysis included 110,885 propensity-matched pairs followed for a mean of 670 days.
The researchers found that the incidence rate for dementia was 0.22 per 100 person-years in initiators of SGLT-2 inhibitors and 0.35 per 100 person-years in initiators of DPP-4 inhibitors (hazard ratios: 0.65 for dementia, 0.54 for dementia requiring drugs, 0.61 for Alzheimer disease, and 0.48 for vascular dementia). Findings persisted regardless of dementia type and across subgroups categorized by age, sex, concomitant use of metformin, and baseline cardiovascular risk. When adjusting for residual confounding (measured by cataract surgery), the risk for dementia remained lower (hazard ratio, 0.70). The association was stronger for treatment of more than two years (hazard ratio, 0.57).
"Highly consistent results over a range of secondary and sensitivity analyses supported the robustness of our study findings," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
ENDO: Guidelines Developed for Pregnancy Care in Preexisting Diabetes
FRIDAY, July 18, 2025 -- In a joint clinical practice guideline issued by the Endocrine Society and European Society of Endocrinology, recommendations are presented for pregnancy...
ENDO: Older Age, Female Sex Tied to Greater Muscle Loss With Semaglutide
THURSDAY, July 17, 2025 -- Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and greater muscle loss is...
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
THURSDAY, July 17, 2025 -- For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with an increased risk for gastroesophageal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.